Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    OK!

    Registration for the Virtual Dialogue is Still Open: Saturday April 30 at 1:00PM EST

    Join Us: Registration is Still Open

    The Chondrosarcoma CS Foundation, Inc. will host their fourth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings and technologies to improve the treatment of Chondrosarcoma.

    In the spirit of sharing and passing knowledge about Chondrosarcoma, we invite you to attend our fourth virtual dialogue. The event is free, there are no fees and all we need is your e-mail address to send you the zoom link.

    Date: Saturday, April 30, 2022
    Time: 1:00PM – 2:30PM (Eastern Standard Time / New York)

    Please register at:
    https://csfshayna.org/virtual-dialogue4-registration/

    INBRX-109 A New Medication to Treat Chondrosarcoma
    Anthony P. Conley, M.D. will review the clinical trials he conducted using INBRX-109, the medication recently granted orphan-drug designation by the FDA to treat conventional chondrosarcoma as well as the future role medications like INBRX-109 will have in treating Chondrosarcoma.

    Using Genetic Sequencing to Predict Prognosis
    William Cross, Ph.D. will discuss genetic mutations found in chondrosarcoma cells that may have direct implications for patient outcome; namely that people with a specific mutation combination (in the genes IDH1 and TERT) do worse, hence they should perhaps be given more attention upfront. He discusses the need for testing the presence of these biomarkers following diagnosis, which is done for other cancer types and is easy and cost effective in the modern oncology clinic.

    Using Patient Registries to Advance Research and Treatment
    Janet Mauro will discuss the NORD: IAMRARE® Patient Registry Platform, currently being used by over 40 Foundation members organizations, nonprofits and advocacy groups representing individuals with rare diseases. She will identify the benefits of implementing a Patient Registry / Natural History Study, the type of information collected and how patient-entered data can be used to advance research and treatment. Ms. Mauro will also address concerns about security, privacy, confidentiality and other relevant issues.

    Please join us for this very informative forum